These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31156161)

  • 1. Influx of Tau and Amyloid-β Proteins into the Blood During Hemodialysis as a Therapeutic Extracorporeal Blood Amyloid-β Removal System for Alzheimer's Disease.
    Kitaguchi N; Tatebe H; Sakai K; Kawaguchi K; Matsunaga S; Kitajima T; Tomizawa H; Kato M; Sugiyama S; Suzuki N; Mizuno M; Takechi H; Nakai S; Hiki Y; Kushimoto H; Hasegawa M; Yuzawa Y; Tokuda T
    J Alzheimers Dis; 2019; 69(3):687-707. PubMed ID: 31156161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective study on blood Aβ levels and the cognitive function of patients with hemodialysis: a potential therapeutic strategy for Alzheimer's disease.
    Kitaguchi N; Hasegawa M; Ito S; Kawaguchi K; Hiki Y; Nakai S; Suzuki N; Shimano Y; Ishida O; Kushimoto H; Kato M; Koide S; Kanayama K; Kato T; Ito K; Takahashi H; Mutoh T; Sugiyama S; Yuzawa Y
    J Neural Transm (Vienna); 2015 Nov; 122(11):1593-607. PubMed ID: 26228626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of Alzheimer's disease amyloid-β in plasma by hemodialysis and its relation to cognitive functions.
    Kitaguchi N; Kawaguchi K; Nakai S; Murakami K; Ito S; Hoshino H; Hori H; Ohashi A; Shimano Y; Suzuki N; Yuzawa Y; Mutoh T; Sugiyama S
    Blood Purif; 2011; 32(1):57-62. PubMed ID: 21346337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Removal of blood amyloid-β with hemodialysis reduced brain amyloid-β, confirmed by brain imaging: a case report.
    Kitaguchi N; Kato T; Matsunaga S; Hirano K; Iwata K; Kawaguchi K; Fujita K; Takechi H; Hasegawa M; Yuzawa Y; Ito K
    Neuropsychiatr Dis Treat; 2018; 14():2931-2937. PubMed ID: 30464477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adsorptive filtration systems for effective removal of blood amyloid β: a potential therapy for Alzheimer's disease.
    Kitaguchi N; Kawaguchi K; Yamazaki K; Kawachi H; Sakata M; Kaneko M; Kato M; Sakai K; Ohashi N; Hasegawa M; Hiki Y; Yuzawa Y
    J Artif Organs; 2018 Jun; 21(2):220-229. PubMed ID: 29230564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential therapeutic system for Alzheimer's disease: removal of blood Aβs by hemodialzyers and its effect on the cognitive functions of renal-failure patients.
    Kato M; Kawaguchi K; Nakai S; Murakami K; Hori H; Ohashi A; Hiki Y; Ito S; Shimano Y; Suzuki N; Sugiyama S; Ogawa H; Kusimoto H; Mutoh T; Yuzawa Y; Kitaguchi N
    J Neural Transm (Vienna); 2012 Dec; 119(12):1533-44. PubMed ID: 22699459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward the treatment for Alzheimer's disease: adsorption is primary mechanism of removing amyloid β protein with hollow-fiber dialyzers of the suitable materials, polysulfone and polymethyl methacrylate.
    Kawaguchi K; Saigusa A; Yamada S; Gotoh T; Nakai S; Hiki Y; Hasegawa M; Yuzawa Y; Kitaguchi N
    J Artif Organs; 2016 Jun; 19(2):149-58. PubMed ID: 26686230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heavy Tau Burden with Subtle Amyloid β Accumulation in the Cerebral Cortex and Cerebellum in a Case of Familial Alzheimer's Disease with APP Osaka Mutation.
    Shimada H; Minatani S; Takeuchi J; Takeda A; Kawabe J; Wada Y; Mawatari A; Watanabe Y; Shimada H; Higuchi M; Suhara T; Tomiyama T; Itoh Y
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model.
    Jin WS; Shen LL; Bu XL; Zhang WW; Chen SH; Huang ZL; Xiong JX; Gao CY; Dong Z; He YN; Hu ZA; Zhou HD; Song W; Zhou XF; Wang YZ; Wang YJ
    Acta Neuropathol; 2017 Aug; 134(2):207-220. PubMed ID: 28477083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
    Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
    Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients that have Undergone Hemodialysis Exhibit Lower Amyloid Deposition in the Brain: Evidence Supporting a Therapeutic Strategy for Alzheimer's Disease by Removal of Blood Amyloid.
    Sakai K; Senda T; Hata R; Kuroda M; Hasegawa M; Kato M; Abe M; Kawaguchi K; Nakai S; Hiki Y; Yuzawa Y; Kitaguchi N
    J Alzheimers Dis; 2016; 51(4):997-1002. PubMed ID: 26923028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease.
    Tzen KY; Yang SY; Chen TF; Cheng TW; Horng HE; Wen HP; Huang YY; Shiue CY; Chiu MJ
    ACS Chem Neurosci; 2014 Sep; 5(9):830-6. PubMed ID: 25054847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subthreshold Amyloid Predicts Tau Deposition in Aging.
    Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ
    J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of selenium, redox status and their association with plasma amyloid/tau in Alzheimer's disease.
    Krishnan S; Rani P
    Biol Trace Elem Res; 2014 May; 158(2):158-65. PubMed ID: 24682919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.
    Xin SH; Tan L; Cao X; Yu JT; Tan L
    Neurotox Res; 2018 Oct; 34(3):733-748. PubMed ID: 29626319
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.